Hence, analyses of the protein sequence for HLA-binding motifs and subsequent testing of blood of tumor patients revealed spontaneous T-cell reactivity against Bcl-2 in patients suffering from unrelated tumor types, i.e., melanoma, pancreatic and breast cancer, as well as AML and B-CLL. This evidence concerns the gene BCL2 and breast cancer.